By Colin Kellaher
Eyenovia on Thursday said it has signed a non-binding letter of intent to combine with clinical-stage pharmaceutical company Betaliq in an all-stock reverse merger.
Eyenovia said Betaliq investors will own about 83.7% of the combined company upon completion of the deal, while its current shareholders would own about 16.3%.
New York ophthalmic-technology company Eyenovia said the proposed transaction assumes a value of about $77 million for Betaliq and roughly $15 million for Eyenovia, which sports a market capitalization of about $3.51 million based on Wednesday's closing price of $1.67.
Trading in shares of Eyenovia was halted premarket on Thursday.
A reverse merger allows a private company to go public by merging with a public one at a lower cost than is involved in traditional initial public offerings.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 20, 2025 07:20 ET (11:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.